Gold is 2025’s best performer. UBS sees more upside
On Thursday, H.C. Wainwright analyst Emily Bodnar revised the price target for Femasys Inc. (NASDAQ:FEMY), a $31.22 million market cap medical device company, to $12.00, down from the previous $15.00, while maintaining a Buy rating on the stock. The adjustment followed Femasys’ disclosure of its first-quarter financial results for 2025 and a corporate update after the market closed the previous day. According to InvestingPro data, analyst targets for FEMY currently range from $3 to $15, reflecting diverse market expectations.
Femasys reported 1Q25 sales of $0.34 million, a figure significantly below H.C. Wainwright’s projection of $1.5 million. This result represents approximately a 70% decrease in revenue compared to the fourth quarter of 2024. The company did not provide detailed revenue breakdowns by product or region. InvestingPro analysis reveals the company maintains a healthy gross profit margin of 66.55%, though it’s currently burning through cash - one of several key insights available to Pro subscribers.
Despite the lower overall sales, Femasys experienced a 78% quarter-over-quarter increase in U.S. revenues, indicating positive trends and growing market presence. The company’s recent partnerships with fertility conglomerates, including a notable agreement with CNY Fertility announced in March 2025, are expected to contribute to sales growth later in the year. With a beta of -2.52, FEMY stock often moves counter to market trends, offering potential diversification benefits.
The gradual implementation of FemaSeed, a key product in Femasys’ portfolio, has been on a center-by-center basis. HRC Fertility, one of the company’s partners, has started promoting FemaSeed on its website, signaling progress in market penetration.
In light of the slower-than-anticipated revenue growth, H.C. Wainwright has reduced its revenue forecast for Femasys in 2025 to $5.3 million from the prior estimate of $10 million. Despite the lowered price target, the firm reaffirmed its Buy rating on the company’s stock.
In other recent news, Femasys Inc. reported its 2024 revenue at $1.6 million, falling short of expectations, with notable contributions from its FemaSeed product following its market introduction. Despite the shortfall, H.C. Wainwright analyst Emily Bodnar remains optimistic, maintaining a Buy rating and increasing the stock price target to $15, citing strategic partnerships like the one with CNY Fertility. This partnership expands FemaSeed’s availability across 11 locations in the U.S., potentially boosting future revenue streams. Femasys also gained CE mark certification for its FemBloc delivery system, marking its first regulatory approval globally, allowing pre-marketing activities in Europe. The company plans to launch FemBloc in select European markets, including Spain, France, Italy, and Germany, ahead of its U.S. introduction. Additionally, Femasys secured UK regulatory approval for three products: FemaSeed, FemVue, and FemCerv, broadening its market reach. These approvals align with Femasys’ strategy to offer innovative women’s health solutions globally. Analysts at H.C. Wainwright project significant revenue growth for FemaSeed, forecasting $11 million in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.